CSI Market
Sign In | Register

Wave Life Sciences Ltd (WVE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access WVE Annual Cash Flow →
Quarterly cash flow trends provide additional context on Wave Life Sciences Ltd's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-95.44
Depreciation & amortization1.70
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation19.80
Income (Loss) from Equity Method Investments0.00
Fair Value of Assets Acquired0.00
Amortization Of Lease Incentive Obligation-
Increase Decrease In Contract With Customer Liability-28.25
Amortization Of Right Of Use Assets1.46
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.39
Increase (Decrease) in Accounts Payable4.86
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-8.32
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense3.73
Other Working Capital1.47
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-40.53
Discontinued operations0.00
Net Cash flow from Operating Activities-113.14
Investing Activities
Capital Expenditures-1.32
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.-122.57
Payments for Tenant Improvements0.00
Proceeds From Government Grant Reimbursements For Property And Equipment-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-123.89
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.86
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Government Grant-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations605.87
At Market Offering Costs In Accounts Payable-
Proceeds From Issuance Of Ordinary Shares Pursuant To At The Market Equity Program Net-
Proceeds From Issuance Of Ordinary Shares Pursuant To The Gsk Collaboration Agreement-
Proceeds From Issuance Of Ordinary Shares Net Of Certain Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.86
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-114.46
Total Cash Flow-234.05
4 historic quarters locked

Sign in to unlock the full Wave Life Sciences Ltd cash flow history.

Sign In Create Free Account

About Wave Life Sciences Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: July 30, 2026
  • Source: wve-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-324949

Figures are derived from filed reports and may be restated. Historical data is subject to revision.